Trial Profile
Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic bronchitis; Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Acronyms REVASC
- 23 Jun 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-005047-27).
- 23 Jun 2012 Company added in the association field, additional lead trial centre identified as reported by EudraCT.
- 23 Jun 2012 Actual initiation date 24 Jan 2012 added as reported by EudraCT.